In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow prevents graft-versus-host disease mortality and permits alloengraftment.
J Exp Med. 1990 Mar 1;171(3):645-58. doi: 10.1084/jem.171.3.645.
J Exp Med. 1990.
PMID: 2307931
Free PMC article.